<DOC>
	<DOC>NCT00738569</DOC>
	<brief_summary>The purpose of this study is to determine whether or not adding Raltegravir to a fully suppressive antiretroviral regimen will assist in reducing HIV-1 associated chronic inflammation and increase the t-lymphocyte memory cell pool.</brief_summary>
	<brief_title>Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen</brief_title>
	<detailed_description />
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1. At least 18 years of age 2. HIVpositive by Western blot or viral load 3. Viral load &lt; 400 copies/ml 4. CD4+ Tlymphocyte count less than 350 cells/mm3 or change in CD4+ Tlymphocyte count &lt; 100 cells/mm3 for at least one year on stable HAART with viral load &lt; 400 copies/ml for the same period of time 1. CD4+ Tlymphocyte count greater than or equal to 350 cells/mm3 or rise in CD4+ Tlymphocyte count greater than or equal to 100 cells/mm3 within one year of study entry 2. Viral load &gt; 400 copies/ml 3. Allergy or resistance to raltegravir</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic inflammation</keyword>
	<keyword>memory cells</keyword>
	<keyword>activated t-lymphocytes</keyword>
</DOC>